Provention Bio to Report Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) announced it will report its third quarter 2020 financial results on November 5, 2020. A live conference call and webcast will occur at 8:00 AM ET to discuss the results and provide a business update. The company focuses on preventing autoimmune diseases, with its lead candidate, teplizumab, under FDA review for delaying insulin-dependent type 1 diabetes in at-risk patients. Investors can access the call by dialing 1-(866)-682-6100 for domestic calls or 1-(862)-298-0702 for international calls.

Positive

• Lead candidate teplizumab is under FDA review, indicating progress in drug development.

Negative

• None.

RED BANK, N.J., Oct. 29, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020.

In connection with the earnings release, Provention's management team will host a live conference call and webcast at 8:00 AM ET on Thursday, November 5, 2020, to discuss the Company's financial results and provide a business update.

Conference Call and Webcast Information:

To access the call, please dial 1-(866)-682-6100 (domestic) or 1-(862)-298-0702 (international) ten minutes prior to the start time and ask to be connected to the "Provention Bio Call." An audio webcast will also be available on the "Events and Webcasts" page of the Investors section of the Company's website, www.proventionbio.com.  An archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for seven days following the call. 

About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The company's lead investigational drug candidate, teplizumab, is currently under review by FDA for the delay or prevention of insulin-dependent type 1 diabetes (T1D) in at-risk patients during the pre-symptomatic phase of the disease. The Company's pipeline includes additional clinical product development candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit ProventionBio.com for more information or follow us on Twitter: @Proventiobio

Investor Contact:
Sam Martin, Argot Partners
sam@argotpartners.com   
212-600-1902

Media:
Lori Rosen, LDR Communications
lori@ldrcommunications.com 
917-553-6808

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-report-third-quarter-2020-financial-results-and-host-conference-call-on-thursday-november-5-2020-301162630.html

SOURCE Provention Bio, Inc.

FAQ

When will Provention Bio report its Q3 2020 financial results?

Provention Bio will report its Q3 2020 financial results on November 5, 2020.

What is the significance of teplizumab for Provention Bio?

Teplizumab is Provention Bio's lead candidate under FDA review for delaying insulin-dependent type 1 diabetes in at-risk patients.

What time is the conference call on November 5, 2020?

The conference call on November 5, 2020, will take place at 8:00 AM ET.

How can investors access the Provention Bio conference call?

Investors can access the conference call by dialing 1-(866)-682-6100 domestically or 1-(862)-298-0702 internationally.